Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 15 December 2015 | By Michael Mezher
Faced with the increasing threat of antimicrobial resistance (AMR), experts are calling for more incentives to boost investment in new antibiotics.
At the FDA/CMS Summit in Washington, DC today, representatives from several companies developing new antibiotic treatments said that while recent initiatives such as the Generating Antibiotics Now Act (GAIN Act) have helped revitalize investment in antibiotic development, more needs to be done to encourage research and development.
The two biggest hurdles for antibiotics, according to the panelists, are poor economic returns compared to other life-saving drugs and not enough market incentives to justify investments.
In 2012, the GAIN Act introduced the new qualified infectious disease product (QIDP) designation for antibiotic and antifungal drugs that treat "serious or life-threatening" infections. Products with QIDP designation automatically receive priority review from FDA and, if approved, "may receive five additional years of marketing exclusivity."
Speaking at the panel, Amanda Jezek, vice president of public policy and government relations at the Infectious Diseases Society of America (IDSA) called the GAIN Act an "important first step." However, Jezek said that other measures, such as the proposed limited-population antibacterial drug (LPAD) pathway in the House-passed version of the 21st Century Cures Act, could do more to boost research and development.
The proposed LPAD pathway would give sponsors of antibiotics intended to treat small patient populations more flexibility to rely on traditional and/or non-traditional endpoints in clinical studies, data from early stages of development such as "preclinical, pharmacologic, or pathophysiologic evidence," as well as data from Phase II trials to support approval.
Barry Eisenstein, a physician specializing in antimicrobials at Merck, pointed to a 2013 commentary he coauthored with infectious disease specialist John Rex, which proposed a four-tier system for determining how much data should be required to support antibiotic approvals.
The panelists agreed that economics pose a major barrier to antibiotic development, saying that low levels of reimbursement and low prices overall make antibiotics a tough sell to investors.
The panelists said they would like to see a value-based pricing system for antibiotics as current payments do not reflect their life-saving potential. Not only are antibiotics inexpensive compared to other drugs, when used appropriately they have the potential to reduce hospital stays, bringing further savings to healthcare systems, they said.
In addition to getting new antibiotic drugs to market, the panelists called for more support for rapid diagnostics that can quickly and accurately identify infections.
Tags: Antimicrobial Resistance, Reimbursement, Limited Population Antibacterial Drug, LPAD, Qualified Infectious Disease Product, QIDP
Regulatory Focus newsletters
All the biggest regulatory news and happenings.